Trial reportInternational urology and nephrology2026
Efficacy of Bushen Qudu Formula in the treatment of uremic pruritus in patients undergoing hemodialysis.
Trial report in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut dysbiosis and constipation in patients with end-stage renal disease: pathogenic associations and therapeutic interventions.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrently, there is no optimal treatment for uremic pruritus, and traditional Chinese medicine (TCM) presents distinct theoretical perspectives and potential advantages. Bushen Qudu Formula has been reported to improve both pruritus and constipation in patients on hemodialysis who have uremia. The aim of this study is to evaluate the therapeutic efficacy of Bushen Qudu Formula on pruritus and constipation in patients undergoing hemodialysis who have uremia, as well as its impact on serum urea nitrogen, C-reactive protein, calcium, phosphorus, and potassium levels.
methodsA survey was conducted on 207 patients on maintenance hemodialysis to assess pruritus and constipation. A total of 139 patients with pruritus were randomly assigned to either the treatment group or the control group. Patients in the treatment group received Bushen Qudu Formula orally, while those in the control group were administered cetirizine orally. Pruritus and constipation scores, as well as changes in serum urea nitrogen, C-reactive protein, calcium, phosphorus, and potassium levels were compared between the two groups of patients.
resultsThe incidence and improvement of pruritus in patients undergoing hemodialysis were positively correlated with the incidence and improvement of constipation. Post-treatment, both groups showed significant improvement in pruritus, with patients in the treatment group showing better results than those in the control group. In the treatment group, there was a significant decrease in the levels of serum urea nitrogen, C-reactive protein, and potassium (P < 0.05), whereas no significant changes were observed in the control group. The differences in serum calcium and phosphorus levels pre- and post-treatment in both groups were not significant (P > 0.05).
conclusionIn this study, it was found that Bushen Qudu Formula was effective in alleviating pruritus and constipation in patients undergoing hemodialysis as well as reducing the levels of serum urea nitrogen, C-reactive protein, and potassium, with no significant effect on serum calcium and phosphorus levels.
Indexed as
Identifiers
40711695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.